ARTICLE | Finance

Disarm and derisk

Disarm’s journey from Atlas seedling to $30M series A

September 22, 2017 4:59 AM UTC

After replicating the effect of sterile alpha and TIR motif containing 1 gene knockout with small molecule SARM1 inhibitors, axon degeneration company Disarm Therapeutics Inc. passed the milestone needed to unlock series A funding from seed investor Atlas Venture.

New investors Lightstone Ventures and AbbVie Ventures also participated in the $30 million A round, which closed on Sept. 19. ...